BioAlta

http://www.bioatla.com/evolution.html?gclid=CMrU9L_ktaACFQMeZwoduW3TTQ

Leading Technologies

A hallmark of BioAtla’s technology is its ability to provide the most complete exploration of protein space through its proprietary Comprehensive Positional Evolution (CPE)™, Combinatorial Protein Synthesis (CPS)™, Synergy Evolution™ and FlexEvolution™.

Comprehensive Positional Evolution (CPE)™

BioAtla’s CPE platform enables the comprehensive mapping of the in vivo effects of every individual codon change within the protein for all 63 potential codon changes at each position within the protein (see figure below).

Combinatorial Protein Synthesis (CPS)™

CPS allows the subsequent generation and in vivo selection of all permutations of improved individual codons for identification of the optimal combination or set of codon changes within a protein or antibody.

Synergy Evolution™

Synergy Evolution™ is the BioAtla evolution strategy designed to identify and engineer improvements in protein function that result from multiple simultaneous changes. This technology is particularly suited for evolving proteins with high assay variability, engineering complex substrate specificity changes and other protein improvements intractable by standard single amino acid protein evolution strategies.

FlexEvolution™

We employ our FlexEvolution™ approach to modify protein characteristics such as solubility, aggregation, deimmunization, glycosylation design and pharmacokinetics that are intractable through traditional approaches.

ClassSwitch™

Immunoglobulin class switching is also referred to as isotype switching, isotypic commutation or class switch recombination. BioAtla’s technologies mimic the natural biological mechanism that changes a B cell’s antibody from one class to another. For example, an IgM can be converted to an IgG or an IgA or an IgE. This process changes the heavy chain of the antibody but retains the heavy chain variable region thus preserving the affinity and antigen specificity of the parent antibody. Class switching allows the new antibody (via new isotype or subtype) to interact with different effector molecules and can open new therapeutic applications.

Types of heavy chain exons (isotypes) include: IgA1, IgA2, IgD, IgE, IgG1 (glycosylated and aglycosylated), IgG2, IgG3, IgG4.

Google Sites

Report abuse